CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleLevered free cash flow is $45.68M, above the global median of $18.73M
- PositionDebt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.07×)
- Interpretations4 currently firing — 4
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.95%Below 5Y avg (1.63%)
Annual Rate
CNY 0.50Paid annual
Payout Ratio
26.4%Sustainable
Last Ex-Dividend
May 29, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
6.70BCNY999.59M · vs all stocks (USD)
Trailing P/E
27.13xvs Biotechnology peers
Revenue (TTM)
1.22BCNY181.96M · vs all stocks (USD)
Profit Margin
20.22%vs Biotechnology peers
Beta
0.4050xvs all stocks
52-Week Change
-30.06%vs all stocks
Market Capitalization
6.70BCNY999.59M · vs all stocks (USD)
Enterprise Value
5.67BCNY845.41M · vs all stocks (USD)
Trailing P/E
27.13xvs Biotechnology peers
Forward P/E
8.42xvs Biotechnology peers
Price to Sales (TTM)
5.49xvs Biotechnology peers
Price to Book (MRQ)
1.85xvs Biotechnology peers
Enterprise to Revenue
4.65xvs Biotechnology peers
Enterprise to EBITDA
16.40xvs Biotechnology peers
Gross Margin
89.19%vs Biotechnology peers
Profit Margin
20.22%vs Biotechnology peers
Operating Margin
32.42%vs Biotechnology peers
Return on Assets (TTM)
4.38%vs Biotechnology peers
Return on Equity (TTM)
7.00%vs Biotechnology peers
Revenue (TTM)
1.22BCNY181.96M · vs all stocks (USD)
Revenue per Share (TTM)
9.38CNYUpdated Sep 21, 2026Quarterly Revenue Growth
5.80%vs Biotechnology peers
Gross Profit (TTM)
1.09BCNY162.97M · vs all stocks (USD)
EBITDA (TTM)
333.74MCNY49.80M · vs all stocks (USD)
Net Income (TTM)
246.53MCNY36.79M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
21.30%vs Biotechnology peers
Operating Cash Flow (TTM)
475.89MCNY71.01M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
306.13MCNY45.68M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.5000CNYUpdated Sep 21, 2026Trailing Annual Dividend Yield
0.95%vs all stocks
5-Year Average Dividend Yield
1.63%vs all stocks
Payout Ratio
26.36%vs Biotechnology peers
Revenue
1.17BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
92.80MCNYFY2025 · Dec 31, 2025Gross Profit
1.07BCNYFY2025 · Dec 31, 2025Operating Income
273.12MCNY40.75M · vs all stocks (USD)
Pre-tax Income
259.74MCNYFY2025 · Dec 31, 2025Income Tax Expense
39.85MCNYFY2025 · Dec 31, 2025Net Income
219.90MCNYFY2025 · Dec 31, 2025EBIT
263.42MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
363.37MCNYFY2025 · Dec 31, 2025Research & Development
118.39MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
556.65MCNYFY2025 · Dec 31, 2025Other Operating Expenses
10.26MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
8.15MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
3.68MCNYFY2025 · Dec 31, 2025EPS (Basic)
1.69CNYFY2025 · Dec 31, 2025EPS (Diluted)
1.69CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
129.95MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
129.95MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
219.90MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
322.80MCNYFY2025 · Dec 31, 2025Free Cash Flow
252.09MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.14BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
219.90MCNYFY2025 · Dec 31, 2025Other Non-cash Items
15.39MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
64.31MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
23.21MCNYFY2025 · Dec 31, 2025Capital Expenditures
-70.72MCNYFY2025 · Dec 31, 2025Purchase of Investments
-810.00MCNYFY2025 · Dec 31, 2025Sale of Investments
1.03BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
147.35MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
179.79MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-226.78MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-136.43MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-183.42MCNYFY2025 · Dec 31, 2025Shares Outstanding
129.95MSharesUpdated Sep 21, 2026Float Shares
86.12MSharesUpdated Sep 21, 2026% Held by Insiders
34.09%vs all stocks
% Held by Institutions
9.81%vs all stocks
Total Cash (MRQ)
1.03BCNY154.18M · vs all stocks (USD)
Total Cash per Share (MRQ)
7.95CNYUpdated Sep 21, 2026Total Debt (MRQ)
0.00CNYvs all stocks (USD)
Total Debt to Equity (MRQ)
0.00xvs Biotechnology peers
Current Ratio (MRQ)
7.65xvs Biotechnology peers
Book Value per Share (MRQ)
27.81CNYUpdated Sep 21, 2026Total Assets
4.01BCNY598.34M · vs all stocks (USD)
Total Current Assets
2.52BCNYFY2025 · Dec 31, 2025Total Liabilities
472.31MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.49BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
32.99MCNYFY2025 · Dec 31, 2025Total Current Liabilities
439.32MCNYFY2025 · Dec 31, 2025Cash
1.15BCNYFY2025 · Dec 31, 2025Cash Equivalents
0.00CNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.15BCNYFY2025 · Dec 31, 2025Accounts Receivable
1.23BCNYFY2025 · Dec 31, 2025Inventory
140.81MCNYFY2025 · Dec 31, 2025Accounts Payable
2.95MCNYFY2025 · Dec 31, 2025Short-term Debt
139.90MCNYFY2025 · Dec 31, 2025Other Current Liabilities
14.06KCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
24.88MCNYFY2025 · Dec 31, 2025Common Stock (Book)
129.95MCNYFY2025 · Dec 31, 2025Retained Earnings
2.48BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
3.54BCNY527.86M · vs all stocks (USD)
52-Week Low
42.31CNYUpdated Sep 21, 202652-Week High
86.50CNYUpdated Sep 21, 202652-Week Change
-30.06%vs all stocks
Beta
0.4050xvs all stocks
50-Day MA
49.18CNYUpdated Sep 21, 2026200-Day MA
58.24CNYUpdated Sep 21, 2026Avg 10-Day Volume
2.47MSharesUpdated Sep 21, 2026Avg 30-Day Volume
4.24MSharesUpdated Sep 21, 2026Diluted EPS (TTM)
1.90CNYUpdated Sep 21, 20264 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
How is this stock valued?
Drawdown With FCF And Cash Backing
Well below its peak, with three years of positive free cash flow behind it.
Reads
High Retained Earnings With Profitability And Equity
Profits kept in the business fund much of what it owns, after five straight profitable years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.07×)Notable
Debt-to-equity: 0.00Industry median: 0.07Industry P5: 0.00Peers compared: 260
Financial Health
Altman Z-Score 10.51: safe zoneNotable
Altman Z-Score: 10.51
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Levered free cash flow is $45.68M, above the global median of $18.73MNotable
Levered free cash flow (USD): 45,680,448.81Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
Pacira BioSciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Anhui Wanbang Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Janux Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sino Medical Sciences Technology Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sunflower Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Monte Rosa Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
0009K0
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shanghai Haohai Biological Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Vor Biopharma Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Northeast Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Castrol India Ltd.
3 interpretationsHigh Retained Earnings With Profitability And EquityCash-Flow Ratios ElevatedIndustry-Benchmarked ROA and Margin Elevated
Concord Biotech Ltd.
3 interpretationsHigh Retained Earnings With Profitability And EquityCash-Flow Ratios ElevatedIndustry-Benchmarked ROA and Margin Elevated
MarketAxess Holdings Inc.
3 interpretationsHigh Retained Earnings With Profitability And EquityCash-Flow Ratios ElevatedDrawdown With FCF And Cash Backing